New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
11:10 EDTFSL, AVNR, CZR, ATVI, BYDHigh option volume stocks; FSL AVNR CZR ATVI BYD
News For FSL;AVNR;CZR;ATVI;BYD From The Last 14 Days
Check below for free stories on FSL;AVNR;CZR;ATVI;BYD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2014
13:58 EDTATVIBrean Capital to hold a conference
Subscribe for More Information
August 29, 2014
12:00 EDTATVITake-Two rises after speculated as potential Activision target
Shares of video game maker Take-Two (TTWO) are rising after an analyst speculated that it could be acquired by another company in the space, Actvision Blizzard (ATVI). WHAT'S NEW: Dan Houser. the co-founder of key Take-Two division Rockstar Games, appears to be quite fond of Hollywood and Los Angeles, as many of Rockstar's games involve that genre, Benchmark analyst Mike Hickey wrote in a note to investors today. Additionally, there is speculation that Take-Two Interactive could be considering a movie based on Rockstar's hit Grand Theft Auto game, according to the analyst, who adds that Rockstar would control the development of the movie. Activision is based near Los Angeles and it may be in the process of entering the movie business, according to Hickey. Activision's possible foray into movies could stem partly from the larger company being interested in Take-Two, Hickey contended. Such an acquisition would be a "no-brainer" for Activision, given Take-Two's strong development talent and intellectual property, along with its nearly $1B in cash and attractive valuation, the analyst stated. He kept Buy ratings on both stocks. PRICE ACTION: In late morning trading, Take-Two rallied 4% to $23.39 and Activision advanced 0.4% to $23.44.
11:29 EDTATVITake-Two calls active, could be Activision takeover target, says Benchmark Co.
Subscribe for More Information
11:21 EDTATVITake-Two could be Activision takeover target, says Benchmark Co.
Subscribe for More Information
August 28, 2014
10:59 EDTCZRCaesar's in talks with creditors to restructure debt load, NY Post reports
The New York Post reports that Caesar's has been in talks to restructure its debt load with its senior creditors. According to sources, the talks would likely give the debt holders positions in the "two newly created pieces of Caesars that hold the most promising assets," which includes the company's online gaming business. Reference Link
09:32 EDTBYD, CZRNevada reports July statewide gaming win up 0.65% to $931.8M
Subscribe for More Information
August 26, 2014
09:02 EDTAVNRConcert Pharmaceuticals achieves $2M milestone for AVP-786
Concert Pharmaceuticals (CNCE) announced that it has achieved a $2M milestone under its development and license agreement with Avanir Pharmaceuticals (AVNR) for the clinical progression of AVP-786. The milestone is a result of Avanir initiating dosing in a Phase 2 clinical trial with AVP-786 for the adjunctive treatment of major depressive disorder. The agreement provides Avanir with worldwide rights to develop and commercialize AVP-786 and other deuterium-modified dextromethorphan compounds. The licensed compounds are believed to have potential for the treatment of neurological and psychiatric disorders. Under the agreement, Concert is eligible to receive additional milestone payments based upon achievement of certain predefined clinical, regulatory and commercial targets. Avanir will continue to have overall responsibility for research, development and commercialization of d-DM compounds, including AVP-786, and Concert is eligible to receive tiered royalties on worldwide sales of any products containing d-DM. The milestone announced today is the second development milestone Concert has earned under the agreement.
09:02 EDTAVNRAvanir initiates AVP-786 phase II study
Subscribe for More Information
August 22, 2014
12:39 EDTAVNRThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
11:59 EDTATVIGameStop surges after Q2 EPS, revenue beat expectations
Subscribe for More Information
August 20, 2014
10:41 EDTFSLInfineon not buying Fairchild or Fairchild, Reuters reports
A source said Infineon (IFNNY) is not buying Fairchild (FCS) or Freescale (FSL) and declined to comment on other potential takeover candidates, Reuters reports. Infineon is seeking to acquire a U.S.-based semiconductor company for about $2B, Reuters and Bloomberg reported today, citing sources. Semtech (SMTC) was listed by Bloomberg as a potential target for Infineon along with Fairchild and Freescale. Reference Link
08:42 EDTATVIActivision Blizzard price target raised to $30 from $24 at Argus
Subscribe for More Information
07:25 EDTFSLFairchild jumps 5% after Bloomberg says Infineon near deal
Shares of Fairchild Semiconductor (FCS) are rallying 5% in pre-market trading to $16.75 after Bloomberg reported that Infineon (IFNNY) is near a deal to buy a U.S. chipmaker for around $2B. Bloomberg listed Fairchild, Semtech (SMTC) and Freescale (FSL) as potential takeover targets in the semiconductor space. The news agency said Infineon could announce an acquisition as early as today.
August 18, 2014
10:29 EDTFSLGoldman cuts sector view on semiconductors to Cautious
Subscribe for More Information
08:04 EDTFSLSemiconductors sector downgraded to Cautious from Neutral at Goldman
Goldman downgraded the Semiconductors sector to Cautious given signs the cycle is turning based on expectations for a slowdown in semiconductor revenue growth, above trend semi unit shipments that should normalize, and stretching lead times. As a result, the analyst sees risk to Q4 estimates and sees further downside of 10%-25% for the SOX (SOX) and downgraded NXP Semiconductors (NXPI) to Sell from Neutral, InvenSense (INVN) to Neutral from Buy, and removed Maxim Integrated (MXIM) from the Conviction Buy List.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use